Has Single-Agent Rituximab Replaced Watch-and-Wait for a Patient With Asymptomatic Low-Grade Follicular Lymphoma?
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference25 articles.
1. No initial therapy for stage III and IV non-Hodgkins lymphomas of favorable histologic types.;Portlock;Ann Intern Med,1979
2. The natural history of initially untreated low-grade non-Hodgkins lymphomas.;Horning;N Engl J Med,1984
3. . The natural history of low grade non-Hodgkins lymphoma and the impact of a no initial treatment policy on survival.;OBrien;QJM,1991
4. . Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe dEtude des Lymphomes Folliculaires. Groupe dEtude des Lymphomes de lAdulte.;Brice;J Clin Oncol,1997
5. . Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial.;Ardeshna;Lancet,2003
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma in the United States;Value in Health;2024-08
2. Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis;Cancer Medicine;2020-06-02
3. Sites of extranodal involvement are prognostic in patients with stage 1 follicular lymphoma;Oncotarget;2017-07-14
4. Patients Older Than 65 Years With Non-Hodgkin Lymphoma Are Suitable for Treatment With 90Yttrium-Ibritumumab Tiuxetan: A Single-Institution Experience;Clinical Lymphoma Myeloma and Leukemia;2015-08
5. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis;Cancer;2015-04-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3